Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.85 |
| ▸ | RAB9A | P51151 | 1/20 | 0.85 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.85 |
| ▸ | EGFR | P00533 | 14/20 | 0.54 |
| ▸ | GALR3 | O60755 | 1/20 | 0.52 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1904096 | 0.92 | TNF (1.00) | TNFRAB9ANOD1EGFRGALR3 | |
| SCHEMBL22862863 | 0.85 | RAB9A (0.78) | TNFRAB9ANOD1EGFRGALR3 | |
| SCHEMBL22862473 | 0.85 | RAB9A (0.78) | TNFRAB9ANOD1EGFRGALR3 | |
| SCHEMBL22862425 | 0.84 | RAB9A (0.76) | TNFRAB9ANOD1EGFRGALR3 | |
| SCHEMBL22862472 | 0.84 | RAB9A (0.76) | TNFRAB9ANOD1EGFRGALR3 | |
| SCHEMBL22862471 | 0.84 | RAB9A (0.76) | TNFRAB9ANOD1EGFRGALR3 | |
| SCHEMBL22862813 | 0.84 | RAB9A (0.76) | TNFRAB9ANOD1EGFRGALR3 | |
| SCHEMBL22862834 | 0.84 | RAB9A (0.76) | TNFRAB9ANOD1EGFRGALR3 | |
| SCHEMBL22862521 | 0.84 | RAB9A (0.76) | TNFRAB9ANOD1EGFRGALR3 | |
| SCHEMBL22862444 | 0.84 | RAB9A (0.76) | TNFRAB9ANOD1EGFRGALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY | 2022-12-08 | — | — | US | disclosed |
| WO-2021002986-A2 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | BAX, TMBIM6, BCL2 | TNF 2254/4885RAB9A 1715/4885NOD1 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.